253 related articles for article (PubMed ID: 22418245)
1. Napsin A is an independent prognostic factor in surgically resected adenocarcinoma of the lung.
Lee JG; Kim S; Shim HS
Lung Cancer; 2012 Jul; 77(1):156-61. PubMed ID: 22418245
[TBL] [Abstract][Full Text] [Related]
2. The Utility of Thyroid Transcription Factor 1 (TTF-1), Napsin A, Excision Repair Cross-Complementing 1 (ERCC1), Anaplastic Lymphoma Kinase (ALK) and the Epidermal Growth Factor Receptor (EGFR) Expression in Small Biopsy in Prognosis of Patients with Lung Adenocarcinoma - A Retrograde Single-Center Study from Croatia.
Piljić Burazer M; Mladinov S; Ćapkun V; Kuret S; Glavina Durdov M
Med Sci Monit; 2017 Jan; 23():489-497. PubMed ID: 28128193
[TBL] [Abstract][Full Text] [Related]
3. The expression of TTF-1 and Napsin A in early-stage lung adenocarcinoma correlates with the results of surgical treatment.
Ma Y; Fan M; Dai L; Kang X; Liu Y; Sun Y; Yan W; Liang Z; Xiong H; Chen K
Tumour Biol; 2015 Sep; 36(10):8085-92. PubMed ID: 25982999
[TBL] [Abstract][Full Text] [Related]
4. Comparative Characteristics of Napsin A, TTF 1 and EGFR Mutation Expression in Mucinous Lung Cell Carcinomas.
Genova SN; Belovezhdov VT; Bichev SN; Danev VH
Folia Med (Plovdiv); 2017 Jun; 59(2):174-182. PubMed ID: 28704186
[TBL] [Abstract][Full Text] [Related]
5. Napsin-A, TTF-1, EGFR, and ALK Status Determination in Lung Primary and Metastatic Mucin-Producing Adenocarcinomas.
Rossi G; Cavazza A; Righi L; Sartori G; Bisagni A; Longo L; Pelosi G; Papotti M
Int J Surg Pathol; 2014 Aug; 22(5):401-7. PubMed ID: 24651909
[TBL] [Abstract][Full Text] [Related]
6. [Clinicopathological and prognostic significance of a panel of tumor biomarkers in lung adenocarcinoma: a tissue microarray study].
Yang X; Xue L; Guo L; Wen P; Lin D
Zhongguo Fei Ai Za Zhi; 2014 Mar; 17(3):243-53. PubMed ID: 24667263
[TBL] [Abstract][Full Text] [Related]
7. Utility of TTF-1 and Napsin-A in the work-up of malignant effusions.
El Hag M; Schmidt L; Roh M; Michael CW
Diagn Cytopathol; 2016 Apr; 44(4):299-304. PubMed ID: 26799356
[TBL] [Abstract][Full Text] [Related]
8. Napsin A expression in primary mucin-producing adenocarcinomas of the lung: an immunohistochemical study.
Wu J; Chu PG; Jiang Z; Lau SK
Am J Clin Pathol; 2013 Feb; 139(2):160-6. PubMed ID: 23355200
[TBL] [Abstract][Full Text] [Related]
9. Lepidic and micropapillary growth pattern and expression of Napsin A can stratify patients of stage I lung adenocarcinoma into different prognostic subgroup.
Yang X; Liu Y; Lian F; Guo L; Wen P; Liu XY; Lin DM
Int J Clin Exp Pathol; 2014; 7(4):1459-68. PubMed ID: 24817941
[TBL] [Abstract][Full Text] [Related]
10. KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.
Kadota K; Sima CS; Arcila ME; Hedvat C; Kris MG; Jones DR; Adusumilli PS; Travis WD
Am J Surg Pathol; 2016 Dec; 40(12):1579-1590. PubMed ID: 27740967
[TBL] [Abstract][Full Text] [Related]
11. ANCCA protein expression is a novel independent poor prognostic marker in surgically resected lung adenocarcinoma.
Zhang Y; Sun Y; Li Y; Fang Z; Wang R; Pan Y; Hu H; Luo X; Ye T; Li H; Wang L; Chen H; Ji H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S577-82. PubMed ID: 23775406
[TBL] [Abstract][Full Text] [Related]
12. Combination of napsin A and TTF-1 immunohistochemistry helps in differentiating primary lung adenocarcinoma from metastatic carcinoma in the lung.
Ye J; Findeis-Hosey JJ; Yang Q; McMahon LA; Yao JL; Li F; Xu H
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):313-7. PubMed ID: 21464700
[TBL] [Abstract][Full Text] [Related]
13. The clinicopathological significance of Lgr5 expression in lung adenocarcinoma.
Ryuge S; Sato Y; Jiang SX; Wang G; Kobayashi M; Nagashio R; Katono K; Iyoda A; Satoh Y; Masuda N
Lung Cancer; 2013 Oct; 82(1):143-8. PubMed ID: 23915911
[TBL] [Abstract][Full Text] [Related]
14. Comparison of monoclonal napsin A, polyclonal napsin A, and TTF-1 for determining lung origin in metastatic adenocarcinomas.
Mukhopadhyay S; Katzenstein AL
Am J Clin Pathol; 2012 Nov; 138(5):703-11. PubMed ID: 23086771
[TBL] [Abstract][Full Text] [Related]
15. CDX-2 Expression in Primary Lung Adenocarcinoma.
Cowan ML; Li QK; Illei PB
Appl Immunohistochem Mol Morphol; 2016 Jan; 24(1):16-9. PubMed ID: 26469326
[TBL] [Abstract][Full Text] [Related]
16. EGFR and TTF-1 gene amplification in surgically resected lung adenocarcinomas: clinicopathologic significance and effect on response to EGFR-tyrosine kinase inhibitors in recurred cases.
Lee JS; Kim HR; Lee CY; Shin M; Shim HS
Ann Surg Oncol; 2013 Sep; 20(9):3015-22. PubMed ID: 23525704
[TBL] [Abstract][Full Text] [Related]
17. Ribonucleic Acid In Situ Hybridization Is a More Sensitive Method Than Immunohistochemistry in Detection of Thyroid Transcription Factor 1 and Napsin A Expression in Lung Adenocarcinomas.
Shi J; Liu H; Ma XJ; Chen Z; He MX; Luo Y; Lin F
Arch Pathol Lab Med; 2016 Apr; 140(4):332-40. PubMed ID: 27028392
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic characteristics and prognostic significance of EGFR and p53 mutations in surgically resected lung adenocarcinomas ≤2 cm in maximal dimension.
Lin MW; Wu CT; Shih JY; Chang YL; Yang PC
J Surg Oncol; 2014 Aug; 110(2):99-106. PubMed ID: 24788590
[TBL] [Abstract][Full Text] [Related]
20. Non-terminal respiratory unit type lung adenocarcinoma has three distinct subtypes and is associated with poor prognosis.
Sumiyoshi S; Yoshizawa A; Sonobe M; Kobayashi M; Sato M; Fujimoto M; Tsuruyama T; Date H; Haga H
Lung Cancer; 2014 Jun; 84(3):281-8. PubMed ID: 24725383
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
